Project Grant R01AI202795
Award Date 8/14/26
Completion Date 7/31/31
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60637, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $810,282 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate combination adjuvants that target trained immunity and the TH1/TH17 immune axis to enhance vaccine efficacy against tuberculosis and other infectious diseases. The research addresses the variable protective efficacy of the currently licensed TB vaccine, Mycobacterium bovis BCG (0–80%...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $717,003 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and assess protective mRNA vaccines against tuberculosis. The project focuses on evaluating the safety, immunogenicity, and protective efficacy of QRNA, a novel mRNA vaccine delivered via QUILA-DOTAP (QTAP), a lipid nanoparticle adjuvant designed for stable mRNA delivery across...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $1,296,750 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel trivalent adjuvanted tuberculosis vaccine. The research will characterize and advance a trivalent TB vaccine candidate consisting of three antigens—PPE20 (RV1387), ESXG (RV0287), and...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Research Institute $1,033,950 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a tuberculosis vaccine regimen optimized to induce lung-resident T cells. The project, titled "A Prime-Pull TB Vaccine Regimen Optimized to Induce Lung-Resident T Cells," focuses on identifying and testing mRNA-lipid nanoparticle vaccine candidates designed to generate...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $736,079 to the University of Chicago on July 8, 2026, for research investigating the role of commensal-reactive gamma delta T cells in anti-tuberculosis immunity under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Role of Commensal-Reactive Gamma Delta T Cells in Anti-Tuberculosis Immunity," examines how specific...
- The National Institute of Allergy and Infectious Diseases awarded $490,704 to the Trustees of Tufts College (doing business as Tufts University School of Medicine) on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop spatial multi-omics methodology predicting granuloma trajectory and bacterial restriction during tuberculosis vaccination. The recipient will use spatial proteomic and transcriptional profiling to map immune cell infiltrates in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $460,625 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune mechanisms underlying BCG vaccine protection against tuberculosis. The research uses Collaborative Cross mouse strains to identify immune signatures associated with vaccine-induced TB protection across genetically diverse host populations. The study focuses on a...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $949,073 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop SNAP-TB, a multivalent tuberculosis subunit vaccine candidate for human translation. The funded work, performed in Fort Collins, Colorado, through August 31, 2031, refines a vaccine formulation leveraging the Spontaneous Nanoliposome Antigen Particlization (SNAP) platform to display...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Methodist Hospital Research Institute a $2.71 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 12, 2025, for research extending through May 31, 2029. This award supports the development and characterization of a novel generation of self-adjuvanted messenger RNA (mRNA) vaccines targeting Mycobacterium tuberculosis (MTB), the causative...